



**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

41 22

JUN - 1 1994

Thomas D. Hoffman
Schering-Plough Corporation
Patent Department, 3-West
One Giralda Farms
Madison, New Jersey 07940-1000

Re: Patent Term Extension
Application for
U.S. Patent No. 4,282,233

NOTICE OF FINAL DETERMINATION

A determination has been made that U.S. Patent No. 4,282,233 issued August 4, 1981, which claims the human drug product Claritin, is eligible for patent term extension under 35 USC § 156. The period of extension has been determined to be two years.

The period of extension has been calculated using the FDA determination of the length of the regulatory review period published in the Federal Register of August 31, 1993. Under 35 USC § 156(c):

$$\begin{aligned}\text{Period of Extension} &= 1/2 (\text{Testing Phase}) + \text{Approval Phase} \\ &= 1/2 (1,395) + 2,356 \\ &= 3,054 \text{ days}\end{aligned}$$

Since the regulatory review period began after the patent issue date, the entire period has been considered. No determination of a lack of due diligence was made.

The two year limitation of 35 USC § 156(g)(6)(C) applies in the present situation because: (1) the patent was issued before the date of enactment (September 24, 1984) of 35 USC § 156; (2) the date an exemption under subsection 505(i) of the Federal Food, Drug and Cosmetic Act involving the approved product became effective (January 6, 1983) was before the date of enactment; and, (3) the date the new drug application was approved (April 12, 1993) was after the date of enactment. Since the period of extension calculated under 35 USC § 156(c) for the patent cannot exceed two years under 35 USC § 156(g)(6)(C), the period of extension will be for two years.

The 14 year exception of 35 USC § 156(c)(3) does not operate to further reduce the period determined above.

A single request for reconsideration of this final determination as to the length of extension of the term of the patent may be made if filed within one month of the date of this notice. Extensions of time under 37 CFR § 1.136(a) are not applicable to this time period. In the absence of such request for reconsideration, the Commissioner will issue to the applicant for extension of the term of Patent No. 4,282,233 a certificate of extension, under seal, for a period of two years.

Upon issuance of the certificate of extension the following information will be published in the Official Gazette:

U.S. Patent No.:	4,282,233
Granted:	August 4, 1981
Applicant:	Frank J. Villani et al.
Owner of Record:	Schering Corporation
Title:	ANTI-HISTAMINIC 11-(4-PIPERIDYLIDENE)-5H-BENZO-[5,6]-CYCLOHEPTA-[1,2-B]-PYRIDINES
Classification:	514/290
Product Trade Name:	Claritin
Term Extended:	Two years

C. E. Van Horn

Charles E. Van Horn
Deputy Assistant Commissioner
for Patent Policy and Projects

cc: Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs (HFY-20)
Food and Drug Administration
5600 Fishers Lane, Room 11-44
Rockville, MD 20857

RE: Claritin

FDA Docket No.: 93E - 0213